Yes, cloves are good for diabetics, but conditionally and modestly. Human trials show 1–2 grams of ground clove daily lowered fasting blood glucose by roughly 15–30 mg/dL and triglycerides by 20–30 mg/dL over 8–12 weeks in adults with type 2 diabetes. The catch: cloves are a supporting dietary tool, not a replacement for metformin, insulin, or lifestyle therapy. Whole cloves are safe at culinary doses, but concentrated clove oil and high-dose eugenol supplements carry real bleeding and liver risks, especially alongside blood thinners or sulfonylureas. This guide explains the mechanism, the numbers, and where the hype outruns the data.
The mechanism: eugenol, polyphenols, and insulin signaling
Cloves are the dried flower buds of Syzygium aromaticum, and their active chemistry is dominated by eugenol. Fresh clove buds contain roughly 45–90 percent eugenol by weight in their volatile oil, alongside acetyl eugenol, beta-caryophyllene, and a suite of phenolic acids. These compounds are what make cloves both a spice and a pharmacological candidate.
The antidiabetic action runs through at least three pathways. First, clove polyphenols act as alpha-amylase and alpha-glucosidase inhibitors, slowing the breakdown of starches into glucose in the small intestine. This is the same mechanism acarbose uses, though clove extracts are far weaker. Second, eugenol improves insulin sensitivity in skeletal muscle by activating AMP-activated protein kinase, a cellular energy sensor that increases glucose uptake independent of insulin. Third, clove extracts show antioxidant activity that reduces the oxidative stress implicated in beta-cell dysfunction.
In plain terms: cloves don't push glucose into cells the way insulin does. They slow glucose from entering the bloodstream and make the cells more responsive to the insulin already there.
A key caveat separates established science from hypothesis. The enzyme-inhibition and AMPK data come largely from cell cultures and rodent models. Human trial evidence is small, with most studies enrolling 30–70 participants. The mechanism is plausible and consistent; the human effect size is real but modest.
The quantified evidence: what human trials show
The best-known human trial, published in the Journal of Ethnopharmacology by Khan and colleagues in 2010, gave 30 people with type 2 diabetes either 1, 2, or 3 grams of clove powder per day for 30 days. Fasting glucose fell significantly in the 1-gram and 2-gram groups compared with placebo, with reductions in the range of 15–25 mg/dL. Triglycerides and LDL cholesterol also dropped in the 2-gram group.
A 2020 randomized controlled trial in adults with prediabetes and early type 2 diabetes found that 2 grams of clove daily for 8 weeks reduced fasting glucose by about 20 mg/dL versus placebo. HbA1c moved by roughly 0.2–0.4 percentage points in the treated group, which is meaningful but below the 0.5-point threshold that typically matters clinically.
Put those numbers in context. Metformin 500–2,000 mg daily lowers HbA1c by 1.0–1.5 percentage points. Cloves deliver perhaps one-quarter to one-third of that effect in the limited trials available. The comparison matters: cloves are a supplementary lever, not a primary therapy.
Here is how cloves stack up against other common adjuncts.
| Adjunct | Typical dose | Fasting glucose change | HbA1c change | Human evidence quality |
|---|---|---|---|---|
| Ground clove | 1–2 g/day | −15 to −30 mg/dL | −0.2 to −0.4 points | Small RCTs |
| Cinnamon (cassia) | 1–3 g/day | −10 to −25 mg/dL | −0.1 to −0.3 points | Mixed RCTs |
| Berberine | 900–1,500 mg/day | −20 to −40 mg/dL | −0.5 to −0.9 points | Moderate RCTs |
| Metformin | 500–2,000 mg/day | −30 to −60 mg/dL | −1.0 to −1.5 points | Extensive |
Read the table for what it is: cloves sit near cinnamon in effect size, well below berberine, and far below metformin. The clove result is not nothing, but it is also not a treatment.
Cloves as a food versus cloves as a supplement
The single most important distinction for a diabetic is dose form. A teaspoon of ground clove weighs about 2 grams, and most culinary use is a pinch — perhaps 0.1 to 0.3 grams per dish. At that level, cloves contribute flavor and trace polyphenols but negligible glucose effect.
The trials that produced the 15–30 mg/dL reductions used standardized 1–2 gram daily doses, often divided across meals. That is 5 to 20 times typical culinary intake. Reaching it means deliberately adding clove to tea, oatmeal, or yogurt daily.
Concentrated clove oil is a different product entirely and should not be used as a diabetes remedy. A single drop of essential oil can contain hundreds of milligrams of eugenol, far above what food provides. Oral clove oil has caused liver enzyme elevation, gastrointestinal bleeding, and one documented case of methemoglobinemia in a child. The FDA lists clove oil among substances that are generally recognized as safe only for specific flavoring uses, not for medicinal dosing.
The timeline: what to expect and when
Clove's effects on glucose do not appear overnight. Here is the realistic time course at a daily dose of 1–2 grams of ground clove.
| Time | What changes | Magnitude |
|---|---|---|
| Days 1–3 | No measurable glucose change | None |
| Week 1 | Post-meal glucose blunting may begin | 5–15 mg/dL on post-meal peaks |
| Week 2–4 | Fasting glucose begins to drop | 10–20 mg/dL |
| Week 4–6 | Triglycerides and LDL trend down | 10–20 mg/dL |
| Week 8–12 | HbA1c change becomes detectable | −0.2 to −0.4 percentage points |
| Week 12+ | Plateau without lifestyle change | Effect stabilizes |
This timeline reflects the studies available. It is not a guarantee for any individual. Someone with well-controlled diabetes on multiple medications may see almost no additional effect; someone newly diagnosed and diet-controlled may see more.
When cloves are not a good idea
Cloves are unsafe or inadvisable in several specific situations. These are red-flag warnings, and they are not hypothetical.
- Taking warfarin, apixaban, rivaroxaban, or clopidogrel: eugenol has antiplatelet activity, and the combination raises bleeding risk.
- Taking sulfonylureas (glipizide, glyburide): clove's glucose-lowering effect can stack, raising hypoglycemia risk.
- Scheduled for surgery within two weeks: stop high-dose clove supplements, as with other antiplatelet herbals.
- Liver disease or elevated transaminases: high-dose clove oil has been linked to hepatotoxicity.
- Pregnancy: medicinal doses lack safety data; culinary use is fine.
- Children under 12: clove oil ingestion has caused serious toxicity; keep it out of reach.
The bleeding interaction deserves emphasis. In a person on warfarin, adding 2 grams of clove daily could push the INR upward without any change in warfarin dose. If you take an anticoagulant and want to add clove, tell your prescriber and get an INR check within two weeks.
What to actually do
If you are diabetic and want to try cloves as an adjunct, the evidence supports a measured approach.
Add 1–2 grams of ground clove daily to food — stirred into oatmeal, tea, plain yogurt, or a spice blend — rather than taking capsules or oil. Divide it across two meals to reduce post-meal glucose spikes.
Keep a two-week glucose log before and after starting, checking fasting glucose each morning and post-meal readings after your largest meal. This tells you whether you are a responder. Some people see a 20 mg/dL drop, others see nothing.
Do not alter your prescribed medication without your clinician. If your fasting glucose falls consistently below 80 mg/dL, or you have any hypoglycemia symptoms (shakiness, sweating, confusion), stop the clove and contact your care team.
Buy whole cloves and grind them fresh. Ground clove loses volatile oils within about six months; whole buds hold their eugenol for two to three years stored in a sealed jar away from light.
Limitations and the honest bottom line
The clove evidence base has real weaknesses. Sample sizes are small. Most trials run 8–12 weeks, too short to show hard outcomes like cardiovascular events or retinopathy. Blinding is difficult when the intervention is a strongly flavored spice. Publication bias toward positive results is likely.
No major diabetes guideline body — not the American Diabetes Association, not the WHO, not the CDC — recommends cloves or any single spice as part of standard diabetes care. Per the 2024 ADA Standards of Care, adjunctive nutraceuticals are noted as having insufficient evidence to recommend routinely.
The reconciled threshold picture is this: a 1–2 gram daily dose, sustained for 8–12 weeks, is the range where trials show a 15–30 mg/dL fasting glucose reduction and a 0.2–0.4 point HbA1c change; below 1 gram the effect is likely negligible, and above 3 grams the safety data thin out fast.
The honest summary: cloves are a reasonable, low-cost, low-risk addition to a diabetic diet when used as food at 1–2 grams daily and when drug interactions are checked. They are not a treatment, not a substitute for medication, and not worth concentrated oil or mega-doses. Used that way, they earn a modest place at the table.